Prolonged dexmedetomidine infusion in critically ill adult patients: a retrospective analysis of a large clinical database

Multiparameter Intelligent Monitoring in Intensive Care III

Yue Zhao¹,², Huaqiang Zhou³, Wulin Tan⁴, Yiyan Song¹, Zeting Qiu¹,³, Si Li³, Shaowei Gao¹, Wenqi Huang¹

¹Department of Anesthesia, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China; ²Department of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou 510317, China; ³Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China

Contribution: (I) Conception and design: S Gao, W Huang, H Zhou; (II) Administrative support: W Huang, S Gao; (III) Provision of study materials or patients: W Huang, S Gao; (IV) Collection and assembly of data: S Gao, Y Zhao, H Zhou, W Tan; (V) Data analysis and interpretation: S Gao, Y Zhao, H Zhou, W Tan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Wenqi Huang; Shaowei Gao. Department of Anesthesia, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan 2 Road, Guangzhou 510080, China. Email: huangwq@sysu.edu.cn; gaoshw5@mail.sysu.edu.cn.

Background: There is no conclusive evidence for the effects of prolonged infusion of dexmedetomidine in critically ill patients. We aimed to investigate the safety of long-term dexmedetomidine infusion in a large critically ill patients cohort from the Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC-III) database.

Methods: We retrospectively extracted records from MIMIC-III database. Dexmedetomidine administration time was the basis for group. Variables were compared by chi-square tests, and Mann-Whitney U test as appropriate. We used logistic regression model for multivariate analysis. Contour maps were drawn to measure rebound of heart rate (HR) and blood pressure (BP).

Results: We finally got 1,946 records including 1,368 distinct individuals. Age, body mass index (BMI), length of stay in hospital, accumulated doses of dexmedetomidine and Sequential Organ Failure Assessment (SOFA) score were independent risk factors of in-hospital mortality (P<0.05). But prolonged dexmedetomidine infusion (≥24 h) and abrupt cessation did not increase in-hospital mortality. Furthermore, the rebound of HR and BP was more likely to occur in patients with prolonged infusion of dexmedetomidine.

Conclusions: Prolonged dexmedetomidine infusion is not related to an increased in-hospital mortality, but it is associated with the rebound effect of HR and BP. Further prospective studies are needed.

Keywords: Dexmedetomidine; Multiparameter Intelligent Monitoring in Intensive Care III database (MIMIC-III database); mortality; rebound effect

Submitted Apr 03, 2018. Accepted for publication Jun 26, 2018.

doi: 10.21037/atm.2018.07.08

View this article at: http://dx.doi.org/10.21037/atm.2018.07.08

Introduction

Dexmedetomidine is becoming more widely used as a sedative-analgescic drug in the recent years (1). It works by highly selectively exciting central α₂-adrenoceptor without inhibitory effects on respiration (2). The US Food and Drug Administration (FDA) approved dexmedetomidine as a short-term analgesia and sedation medication (<24 h) in the intensive care unit (ICU) (3). The reason for its short-term use was mainly due to the risk of withdrawal side effects (e.g., rebound tachycardia and hypertension). Previous researches
had revealed no significant increased mortality in critically ill patients treated with dexmedetomidine compared with lorazepam or midazolam (4-6). Some studies also confirmed that dexmedetomidine has a reduction in the length of stay in the ICU compared with other routine agents (7-9). Nowadays, long-term (≥24 h) use of dexmedetomidine in the ICU is common in clinical practice. Several studies had focused on the medication time of dexmedetomidine. Fluctuations of heart rate (HR) and blood pressure (BP) after an abrupt discontinuation of dexmedetomidine have been always observed (10-13). However, the sample size of studies mentioned above was small and there was no reporting of hospital mortality following prolonged infusion of dexmedetomidine.

Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC-III) database is an open accessible critical care database comprising deidentified clinical data associated with over 40,000 patients who admitted in the ICU of the Beth Israel Deaconess Medical Center from 2001 to 2012 (14). The MIMIC-III database includes millions of records about demographics, diagnoses, vital signs, laboratory measurements, medications, survival data, etc.

In the present study, we aimed to investigate the safety of prolonged dexmedetomidine infusion in a large ICU patients cohort from the MIMIC-III database, including the effect on the hospital mortality and the withdrawal reaction.

Methods

Database

We used the MIMIC-III database (version 1.4) for the study. MIMIC-III was approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center (Boston, MA, USA) and the Massachusetts Institute of Technology (Cambridge, MA, USA). Informed consent was waived because of the nature of observation study and all deidentified protected health information. The author Gao and Zhou have got access to the database after completion of the training course “Protecting Human Research Participants” (certification number: 5999328 and 5965432).

Study population

Adult patients receiving dexmedetomidine were included in our study. The inclusion criteria were: (I) patients who were older than 18 years old, we also excluded patients who were over 89 years because MIMIC-III database has shifted their date of birth to obscure their age; (II) length of stay in the ICU was over 24 h; (III) patients with dexmedetomidine medication by continuous slow infusion (IV drip or IV pump); (IV) the infusion time of dexmedetomidine lasts for at least 1 h and no more than 100 h, because of more record and calculation errors due to long term intermittent administration (like >100 h). For patients who were admitted to the ICU more than once, we set individual ICU admission as the basic sampling unit, but not individual patients. Therefore, the same patient may be included repeatedly with different ICU admissions.

Data extraction

We performed the data extraction by using structure query language (SQL) with pgAdmin PostgreSQL tools (version 1.22.1) (15). Following health information were extracted: age, gender, weight and height at the first ICU admission, length of stay in hospital, length of stay in the ICU, hospital expire flag (in-hospital death recorded in the hospital database), BP, HR. The age was accurate to day. We calculated the body mass index (BMI) as weight in kilograms divided by the square of the height in meters. Furthermore, we calculated the Sequential Organ Failure Assessment (SOFA) scores for each patient, which represented the severity of illness and determine the extent of a person’s organ function (16). We obtained the list of anonymized patients using dexmedetomidine from the table inputevents_cv, inputevents_mv and chartevents by the corresponding ITEMIDs.

- chartevents: 1713, 2091, 2166, 2188, 2195, 2196, 2201, 2283, 2296, 2547, 8192
- inputevents_cv: 30167, 42062, 41962, 42407, 43136, 46301, 46492
- inputevents_mv: 225150

Dexmedetomidine administration time was calculated as the endpoint minus start timestamp according to continuous medication records. Besides, we also calculated accumulated doses of dexmedetomidine for all patients. We defined it as gradual reduction when the infusion rate at the endpoint is no more than half of the maximum infusion rate. Otherwise, we regarded it as an abrupt cessation. The primary outcome of present study was death in the hospital. These deaths included both death in ICU and hospital. The secondary outcome was the rebound effect of BP and HR.

Missing data handling

It is common with missing data in the MIMIC-III database.
If a variable had less than 5% missing, the missing observations were omitted directly in further analysis. As for those variables with more than 5% observations missing, we explored and visualized them with Templ's method (R Package “VIM”) (17). For randomly missing data, we used multiple imputation method (R Package “mice”) for further analysis (18).

**Statistical analysis**

We grouped patients by different dexmedetomidine administration time: <24 and ≥24 h. Other variables were displayed and compared between groups. We performed multivariate analysis to determine the impact of prolonged administration of dexmedetomidine on in-hospital mortality. Independent risk factors to in-hospital mortality were revealed and confounding factors were excluded.

To explore the withdrawal reaction, we extracted all records of HR and BP during 48 h after discontinuance of dexmedetomidine. Contour maps were drawn by R package “ggplot2” to measure the fluctuations of HR and BP (records during 48 h after discontinuance minus the mean records during infusion) (19). Local polynomial regression fitting were applied to build the contour maps (20).

The binary variables were compared using chi-square tests. The ordinal categorical variables and continuous variables were compared using Mann-Whitney U test. We used logistic regression model for multivariate analysis. All statistics and visualizations were performed using R version 3.3.1 software (Institute for Statistics and Mathematics, Vienna, Austria; https://www.r-project.org/). Statistical significance was set at two-sided P<0.05.

**Results**

We finally got 1,946 records including 1,368 distinct individuals. They were at the age from 18.23 to 89.72 and the median age was 61.36. The infusion rate was less than 2 μg/kg/h in more than 99.7% cases, and the median rate was 0.50 μg/kg/h. The total in-hospital mortality rate was 5.6%.

The baseline characteristics were briefly summarized in Table 1. There were 1,417 records with a prolonged dexmedetomidine infusion over 24 h, and 529 records

<table>
<thead>
<tr>
<th>Variables</th>
<th>&lt;24 h (n=1,417)</th>
<th>≥24 h (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.04 (18.23–88.72)</td>
<td>60.94 (18.42–88.12)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>421</td>
<td>152</td>
</tr>
<tr>
<td>Female</td>
<td>996</td>
<td>377</td>
</tr>
<tr>
<td>LOS* (days)</td>
<td>9.63 (1.01–153.92)</td>
<td>15.89 (1.12–94.84)</td>
</tr>
<tr>
<td>LOI** (days)</td>
<td>3.45 (1.00–153.93)</td>
<td>10.56 (1.00–79.11)</td>
</tr>
<tr>
<td>SOFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m^2)</td>
<td>28.31 (13.34–77.07)</td>
<td>29.46 (15.93–70.41)</td>
</tr>
</tbody>
</table>

In-hospital death

<table>
<thead>
<tr>
<th></th>
<th>&lt;24 h (n=1,417)</th>
<th>≥24 h (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>61</td>
<td>42</td>
</tr>
<tr>
<td>Alive</td>
<td>1,356</td>
<td>487</td>
</tr>
</tbody>
</table>

Drug withdrawal

<table>
<thead>
<tr>
<th></th>
<th>&lt;24 h (n=1,417)</th>
<th>≥24 h (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrupt cessation</td>
<td>855</td>
<td>249</td>
</tr>
<tr>
<td>Gradual reduction</td>
<td>551</td>
<td>274</td>
</tr>
</tbody>
</table>

Total dose: 200 (90.52–454.77) 1,806 (814.1–3,152)

*Continuous variables display as median (first quartile–third quartile); categorical variables display as count (percentage); *length of hospital stay; **length of ICU stay. ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; BMI, body mass index.
Patients with prolonged dexmedetomidine infusion had a longer stay in hospital and ICU (15.89 vs. 9.63 days; 10.56 vs. 3.45 days; P<0.001). We observed a higher SOFA score in prolonged dexmedetomidine infusion group (P<0.01). More importantly, prolonged dexmedetomidine infusion group had a higher risk of in-hospital death (P<0.01). We could not find difference between groups when considering other variables, including age (P=0.37), gender (P=0.72), and BMI (P=0.89).

The results of multivariate analysis were summarized in Table 2. Age, BMI, length of stay in hospital, accumulated doses of dexmedetomidine and SOFA score were independent risk factors of in-hospital mortality (P<0.05). Interestingly, prolonged dexmedetomidine infusion and gradual cessation did not increase in-hospital mortality, the same as gender and length of stay in ICU (P>0.05).

Fifty-two thousand and seven hundred fifty-five records of HR, 68,349 records of systolic BP (SBP) and 52,808 records of diastolic BP (DBP) after dexmedetomidine discontinuance were extracted. Figure 1 showed the fluctuations under distinct dexmedetomidine medication time and discontinuance time. For HR, the most violent rebound (13–14 bps) could be observed several hours after continuous infusion of dexmedetomidine for about 25 or more hours, and lasted about 20 to 35 h (Figure 1A). For SBP, the most violent rebound (about 8 mmHg) appeared several hours after continuous infusion of dexmedetomidine for about 15 to 40 h, and lasted about 30 h (Figure 1B). And for DBP, the violent rebound (about 5 mmHg) came 15 h after continuous infusion of dexmedetomidine for about 30 or more hours, and lasted about 20 h (Figure 1C).

### Discussion

There is no conclusive evidence for the safety of long-term dexmedetomidine infusion. In the present study, we investigated the safety of long-term dexmedetomidine infusion, by mining the MIMIC-III database. We detected that age, in-hospital time, SOFA score and BMI were independent risk factors for in-hospital mortality. It was consistent with the mainstream views (21-23). Patients with long-term infusion and abrupt cessation were not exposed to an increased in-hospital mortality, but accumulated doses of dexmedetomidine were related with a higher risk of in-hospital mortality. Notably, higher accumulated doses were not equal to prolonged infusion. Thus, when we consider the safety of dexmedetomidine, we may need to focus on the total doses in addition to the usage time. Abrupt cessation or gradual reduction may affect the safety of medicines, but which was not observed in our study. The potential reason may be that the dosage of dexmedetomidine is relatively fixed, and the rate of 0.2–0.7 ug/kg/h is commonly used for sedative maintenance in clinical practice.

With the contour maps, we showed the rebound effect of HR and BP at the circumstance of distinct medication time and cessation time. The rebound effects were more likely to be concentrated on the prolonged medication group. In other words, our study supports that the rebound of HR and BP is more likely to occur in patients with prolonged infusion of dexmedetomidine. However, we could not

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.03 (1.01–1.05)</td>
<td>0.0005</td>
</tr>
<tr>
<td>Male gender</td>
<td>0.75 (0.44–1.29)</td>
<td>0.2982</td>
</tr>
<tr>
<td>LOS*</td>
<td>1.03 (1.01–1.05)</td>
<td>0.0033</td>
</tr>
<tr>
<td>LOI**</td>
<td>1.01 (0.98–1.04)</td>
<td>0.5172</td>
</tr>
<tr>
<td>SOFA</td>
<td>1.16 (1.08–1.25)</td>
<td>0.0001</td>
</tr>
<tr>
<td>BMI</td>
<td>0.94 (0.90–0.98)</td>
<td>0.0055</td>
</tr>
<tr>
<td>LODex***</td>
<td>0.89 (0.48–1.65)</td>
<td>0.7115</td>
</tr>
<tr>
<td>Gradual reduction</td>
<td>1.31 (0.80–2.17)</td>
<td>0.2863</td>
</tr>
<tr>
<td>Total dose</td>
<td>1.00015 (1.00002–1.00028)</td>
<td>0.0194</td>
</tr>
</tbody>
</table>

* LOI, length of hospital stay; ** LOI, length of ICU stay; *** LODex, length of dexmedetomidine infusion (≥24 h). ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; BMI, body mass index.
observe a 20% clinically significant rebound of SBP or HR. Previous studies reported mild increase after terminating the infusion of dexmedetomidine. Carney et al. and Shehabi et al. found patients receiving dexmedetomidine for more than 24 h were more likely to have hypertension, which were similar with our study (10,12). On the contrary, Ozaki et al. supported that the increase of mean arterial BP and HR after cessation of dexmedetomidine was not associated with the increasing infusion time (13). All studies above had the limited sample size.

One strength of the present study is the data mining of a large critical care database MIMIC-III, with large sample size. The secondary analysis of “real world” data may be more generalizable compared with the strict and well-designed RCTs (24,25). In addition, there are some limitations in the present study. First, our study is a retrospective analysis, it is inevitable to bear some inherent limitations of such design. Second, critically ill patients are heterogeneous, unknown factors may still confound the results even though we have adjusted the confounding factors by multivariate analysis. Finally, we set the “in-hospital mortality” as the study outcome, which it reflected the short-term outcomes. So, the relationship of dexmedetomidine and long-term outcomes is still unclear.

Conclusions

In conclusion, the study shows that prolonged dexmedetomidine infusion is not related to an increased in-hospital mortality, but it is associated with the rebound effects of heart rate and blood pressure. The findings require further prospective studies to confirm.

Acknowledgements

The authors appreciate the efforts of the Medical Information Mart for Intensive Care III Database. Thanks to all code contributors in GitHub across the world as well as researchers at the MIT Laboratory for Computational Physiology and collaborating research groups.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figure 1 The contour plots for the rebound of HR and BP at the circumstance of distinct medication time and cessation time. The rainbow spectrum measures the degree of rebound (hot for violent rebound and cold for slight rebound). Points on the same line have same degree of rebound. (A) indicates the HR rebound; (B) for the systolic BP; and (C) for the diastolic BP. HR, heart rate; BP, blood pressure.
References
